Amgen 4Q Revenues: $3.7 billion (-2%) 4Q Earnings: $835 million (flat) FY Revenues: $14.8 billion (+4%) FY Earnings: $3.2 billion (+7%) Comments: Worldwide Aranesp sales were down 25% to $827 million in 4Q07, due to a decline in U.S. demand. FY Aranesp sales were $3.6 billion (-12%). Sales of Epogen were down 3% to $638 million in the quarter and were $2.5 billion for the year (-1%). Combined worldwide sales of Neulasta and Neupogen were $1.1 billion in the quarter (+9%), and $4.3...